Brief Introduction on Aderse Drug Reaction Monitoring at the Grass-root Level

[1]

ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.

[2]

GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.

[3]

TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.

[4]

HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia. 535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.

[5]

HUANG Cuili, GAO Ao, WANG Jiaxi, GUO Haili, XU Xiaohan, CHENG Yinchu, GUO Daihong. Automatic monitoring and assessment of antibiotics-related thrombocytopenia [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 807-811.

[6]

LIU Yuanxi, GU Donglin, WANG Qi, YAO Lingwen, WANG Ying, JIN Hongyu, MA Shuangcheng. Determination of 87 types of pesticide residues in Polygoni Multiflori Radix by LC-MS/MS [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 601-608.

[7]

ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang. Applicability of patient registry research to regulation of medical devices [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.

[8]

ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong. Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.

[9]

WANG Jiaxi, GUO Daihong, ZHANG Bo, Li Boyan, GUO Haili. Automatic monitoring and risk factors of acute kidney injury in 116097 dosing cases of flurbiprofen axetil [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 201-205.

[10]

TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384.

[11]

ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.

[12]

ZUO Tiantian, WANG Zhao, GUO Yuansheng, WEI Feng, JIN Hongyu, MA Shuangcheng. Non-carcinogenic and carcinogenic risk assessment of toxic elements in Panax quinquefolium L. based on multi-element semi-quantitative screening [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1108-1112.

[13]

ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia. Thyroid immune-related adverse reactions of immune checkpoint inhibitors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.

[14]

XUN Xiaoqing, PENG Lingling. Effects of sodium valproate on children with epilepsy and determinants of blood concentrations [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1027-1029.

[15]

ZHUANG Hongyan, ZANG Yannan, LIU Shanshan, NIU Mengxi, FANG Meng, YIN Dongqing, GUO Wei. Analysis of neuropsychiatric adverse reactions caused by zolpidem [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 889-892.

PDF (PC)